<DOC>
	<DOCNO>NCT01134523</DOCNO>
	<brief_summary>To compare efficacy safety EC-T ET regimen adjuvant treatment breast cancer patient positive lymph node</brief_summary>
	<brief_title>Regimens Comparison Breast Cancers Positive Lymph Nodes</brief_title>
	<detailed_description>EC-T regimen : epirubicin 90mg/m2 day1 , CTX 600mg/m2 , day 1 , 21 day per cycle *4cycle . follow paclitaxel 175mg/m2 , d1,21days per cycle , 4 cycle . ET regimen : epirubicin 75mg/m2 day1 , paclitaxel 175mg/m2 , d2,21days per cycle , 6 cycle</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>patient breast cancer breast cancer surgery positive lymph node age 1870 year old malignance disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>positive lymph node</keyword>
</DOC>